When is the next results date for Rainbow Child.?

No Upcoming Board Meetings

Has Rainbow Child. declared dividend?

Rainbow Childrens Medicare Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of June 27, 2025. The dividend yield is 0.21%, and total returns have varied across periods, showing significant growth over the long term despite short-term declines.

Rainbow Childrens Medicare Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 27 Jun 25<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -14.08%, the dividend return was 0.18%, resulting in a total return of -13.9%.<BR><BR>Over the past year, the price return was 8.36%, the dividend return was 0.46%, leading to a total return of 8.82%.<BR><BR>In the 2-year period, the price return was 52.26%, the dividend return was 0.94%, culminating in a total return of 53.2%.<BR><BR>For the 3-year period, the price return was 196.48%, the dividend return was 2.53%, resulting in a total return of 199.01%.<BR><BR>In the 4-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Similarly, in the 5-year period, there was no price return, no dividend return, and a total return of 0.0%.<BR><BR>Overall, Rainbow Childrens Medicare Ltd has declared a dividend and has shown varying total returns across different periods, with significant growth in the longer terms despite some negative performance in the short term. The dividend yield indicates a modest return relative to the share price.

Is Rainbow Child. overvalued or undervalued?

As of June 12, 2023, Rainbow Child is considered very expensive and overvalued with a PE ratio of 58.94, a Price to Book Value of 9.77, and an EV to EBITDA ratio of 29.64, despite a strong three-year stock performance of 199.47%.

As of 12 June 2023, the valuation grade for Rainbow Child. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 58.94, a Price to Book Value of 9.77, and an EV to EBITDA ratio of 29.64. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Rainbow Child. has a higher PE ratio than Max Healthcare Institute Ltd. at 100.29 and Apollo Hospitals Enterprise Ltd. at 69.03, both of which are also categorized as very expensive. The PEG ratio of 4.86 further underscores the overvaluation, especially when compared to peers like Narayana Hrudayalaya Ltd. with a PEG of 37.59. Despite a strong stock performance over the past three years, with a return of 199.47%, the current valuation metrics indicate that Rainbow Child. is not justified at its current price of 1408.40.

Who are the peers of the Rainbow Child.?

Peers of Rainbow Child include Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Dr. Agarwal's Health, Jupiter Life Line, Health.Global, and Kovai Medical. Rainbow Child has good management risk and a 1-year return of 29.99%, lower than Fortis Health's 62.86%.

Peers: The peers of Rainbow Child are Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Dr Agarwal's Hea, Jupiter Life Lin, Health.Global, and Kovai Medical.<BR><BR>Quality Snapshot: Excellent management risk is observed at Narayana Hrudaya, Global Health, Dr Agarwal's Hea, Jupiter Life Lin, and Kovai Medical, while Average management risk is found at Fortis Health. Good management risk is noted for Rainbow Child and Health.Global. In terms of growth, Good growth is seen at Narayana Hrudaya, Dr Agarwal's Hea, and Health.Global, while Below Average growth is present at Aster DM Health., Rainbow Child, Krishna Institu., and Kovai Medical. For capital structure, Excellent capital structure is noted at Global Health and Krishna Institu., while Good capital structure is observed at Fortis Health, Rainbow Child, Dr Agarwal's Hea, and Kovai Medical, with Below Average capital structure at Aster DM Health. and Health.Global.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 62.86%, while the lowest is Dr Agarwal's Hea with N/A, and Rainbow Child's 1-year return of 29.99% is lower than Fortis Health's. Additionally, Jupiter Life Lin has a negative six-month return of -3.18%.

Who are in the management team of Rainbow Child.?

As of March 2023, the management team of Rainbow Child includes Ramesh Kancharla (Chairman & Managing Director), Dinesh Kumar Chirla (Whole-time Director), and five Independent Directors: Aluri Rao Srinivasa, Anil Dhawan, Sundari Raviprasad Pisupati, Santanu Mukherjee, and Ashish Kapil (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2023, the management team of Rainbow Child includes the following individuals:<BR><BR>1. Ramesh Kancharla - Chairman & Managing Director<BR>2. Dinesh Kumar Chirla - Whole-time Director<BR>3. Aluri Rao Srinivasa - Independent Director<BR>4. Anil Dhawan - Independent Director<BR>5. Sundari Raviprasad Pisupati - Independent Director<BR>6. Santanu Mukherjee - Independent Director<BR>7. Ashish Kapil - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Rainbow Child. do?

Rainbow Childrens Medicare Ltd is a mid-cap company in the hospital industry, reporting net sales of 3,701 Cr and a net profit of 563 Cr for the quarter ending March 2025. It has a market cap of INR 15,613 Cr, a P/E ratio of 64.00, and a dividend yield of 0.40%.

Overview:<BR>Rainbow Childrens Medicare Ltd operates in the hospital industry and is categorized as a mid-cap company.<BR><BR>History:<BR>The company was originally incorporated as Rainbow Children's Medicare Private Limited in 1998 and later converted to a public limited company, changing its name to Rainbow Children's Medicare Limited on November 20, 2021. The most recent quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 3,701 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 563 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 15,613 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 64.00<BR>- Industry P/E: 59<BR>- Dividend Yield: 0.40%<BR>- Debt Equity: 0.12<BR>- Return on Equity: 16.58%<BR>- Price to Book: 10.50<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are the top shareholders of the Rainbow Child.?

The top shareholders of Rainbow Child include Ramesh Kancharla with 31.04%, 23 mutual funds holding 11.47%, and 188 foreign institutional investors with 23.69%. The highest public shareholder is the DSP Aggressive Hybrid Fund at 4.27%, while individual investors own 10.34% of the shares.

The top shareholders of Rainbow Child include the promoters, with Ramesh Kancharla holding the highest individual stake at 31.04%. Additionally, the company has significant institutional investment, with 23 mutual funds collectively holding 11.47% and 188 foreign institutional investors (FIIs) holding 23.69%. The highest public shareholder is the DSP Aggressive Hybrid Fund, which holds 4.27%. Individual investors also have a notable presence, owning 10.34% of the shares.

How big is Rainbow Child.?

As of 24th July, Rainbow Childrens Medicare Ltd has a market capitalization of 15,730.00 Cr, with recent net sales of 1,515.87 Cr and a net profit of 243.43 Cr. Shareholder's funds are 1,468.19 Cr and total assets are 2,347.40 Cr as of March 2025.

As of 24th July, Rainbow Childrens Medicare Ltd has a market capitalization of 15,730.00 Cr and is classified as a Mid Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 1,515.87 Cr and a Net Profit of 243.43 Cr.<BR><BR>For the latest annual period ending March 2025, the Shareholder's Funds amounted to 1,468.19 Cr, while the Total Assets were reported at 2,347.40 Cr.

Are Rainbow Child. latest results good or bad?

Rainbow Children's Medicare's latest results show mixed performance: while operating cash flow and dividends are at their highest in years, profit before tax and net sales have declined significantly, indicating areas of concern despite some positive indicators. Overall, the performance appears flat with notable challenges ahead.

The latest results for Rainbow Childrens Medicare present a mixed picture. On one hand, there are some positive indicators, such as an annual operating cash flow of Rs 385.05 crore, which is the highest in the last three years, and a debt-equity ratio of 0.52 times, the lowest in recent periods. Additionally, the company has declared a dividend of Rs 3.00 per share, the highest in five years, signaling a commitment to returning profits to shareholders.<BR><BR>However, there are notable concerns as well. Profit Before Tax (PBT) has decreased by 26.4% to Rs 51.35 crore, and Profit After Tax (PAT) has fallen by 12.1% to Rs 53.50 crore. Furthermore, net sales have declined by 6.9% to Rs 352.93 crore. While the company has shown some stabilization in its overall score, the downward trends in profitability and sales are significant.<BR><BR>In summary, while there are some positive developments, the overall performance can be seen as flat with areas of concern that may need to be addressed moving forward.

How has been the historical performance of Rainbow Child.?

Rainbow Child has shown consistent growth over the past six years, with net sales increasing from 650.05 Cr in Mar'21 to 1,515.87 Cr in Mar'25, and profit after tax rising from 39.57 Cr to 244.23 Cr. The company has eliminated long-term debt and improved cash flow, indicating strong financial health.

Answer:<BR>The historical performance of Rainbow Child shows a consistent growth trend across various financial metrics over the past six years.<BR><BR>Breakdown:<BR>Rainbow Child's net sales have increased significantly from 650.05 Cr in Mar'21 to 1,515.87 Cr in Mar'25, reflecting a strong upward trajectory. Total operating income followed a similar trend, rising from 719.39 Cr in Mar'20 to 1,515.87 Cr in Mar'25. The company's operating profit (PBDIT) also saw substantial growth, climbing from 173.10 Cr in Mar'21 to 540.90 Cr in Mar'25, although the operating profit margin slightly decreased from 33.07% in Mar'24 to 32.32% in Mar'25. Profit before tax rose from 55.70 Cr in Mar'21 to 330.00 Cr in Mar'25, while profit after tax increased from 39.57 Cr in Mar'21 to 244.23 Cr in Mar'25, showcasing improved profitability. The total assets of the company grew from 1,018.89 Cr in Mar'20 to 2,347.40 Cr in Mar'25, indicating a solid expansion in the asset base. Furthermore, the company has eliminated long-term borrowings, achieving a total debt of 0.00 Cr in Mar'25, which reflects a strong financial position. Cash flow from operating activities has also improved, rising from 142.00 Cr in Mar'21 to 395.00 Cr in Mar'25, contributing to a net cash inflow of 10.00 Cr in Mar'25. Overall, Rainbow Child has demonstrated robust growth and financial health over the years.

Should I buy, sell or hold Rainbow Child.?

Is Rainbow Child. technically bullish or bearish?

As of December 1, 2025, the technical trend is mildly bearish, influenced by bearish indicators from the weekly MACD and moving averages, despite some bullish momentum in the weekly RSI and mixed monthly signals.

As of 1 December 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and Bollinger Bands indicating bearish conditions, while the daily moving averages also reflect a bearish outlook. The weekly RSI shows bullish momentum, but the overall monthly indicators remain mixed, with the KST showing bullish on a monthly basis. Dow Theory suggests a mildly bullish stance on the weekly timeframe, but with no clear trend on the monthly. The stock's recent performance against the Sensex has been negative across multiple time frames, further supporting the bearish sentiment.

Which are the latest news on Rainbow Child.?

Why is Rainbow Child. falling/rising?

As of 21-Dec, the stock price of Rainbow Childrens Medicare Ltd is declining, currently at 1,315.20, reflecting a bearish trend with significant underperformance compared to the market. The stock has seen a year-to-date drop of 12.21% and a notable decrease in investor interest, contributing to its negative outlook.

As of 21-Dec, the stock price of Rainbow Childrens Medicare Ltd is falling, currently at 1,315.20, which reflects a decrease of 9.8 points or 0.74%. This decline is evident in the stock's performance over various periods, showing a 5.03% drop over the past week and a 1.90% decrease over the past month. Year-to-date, the stock has fallen by 12.21%, significantly underperforming the Sensex, which has gained 8.69% in the same timeframe.<BR><BR>The stock is also trading below its moving averages across multiple timeframes, indicating a bearish trend. Additionally, there has been a notable decline in investor participation, with delivery volume dropping by 58.11% compared to the 5-day average, suggesting reduced interest from investors.<BR><BR>Despite some positive factors, such as high management efficiency and strong debt servicing capabilities, the overall outlook remains negative. The company's operating profit growth rate of 14.50% over the last five years is considered poor for long-term growth, and its valuation appears expensive with a PEG ratio of 5.5. Furthermore, the stock has underperformed the broader market, generating a return of -16.26% over the past year while the market has seen positive returns.<BR><BR>In summary, the combination of poor recent performance, declining investor interest, and unfavorable comparisons to market benchmarks contributes to the falling stock price of Rainbow Childrens Medicare Ltd.

Why is Rainbow Child. falling/rising?

As of 22-Dec, the stock price of Rainbow Childrens Medicare Ltd is at 1,358.80, up 2.39% today, driven by short-term gains despite a decline in investor participation. The stock has outperformed its sector and shown consecutive gains over the last three days, but longer-term challenges remain.

As of 22-Dec, the stock price of Rainbow Childrens Medicare Ltd is rising, currently at 1,358.80, reflecting an increase of 31.75 or 2.39%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 1.31% today and has shown a consecutive gain over the last three days, accumulating a total return of 3.37% during this period. Additionally, the stock reached an intraday high of Rs 1363.9, marking a rise of 2.78%. <BR><BR>Despite these positive indicators, it is important to note that the stock has experienced a decline in investor participation, with delivery volume falling by 33.93% against the 5-day average. However, the stock remains liquid enough for trading, based on its average traded value. Overall, the recent gains in stock price are primarily driven by short-term performance metrics, despite longer-term challenges reflected in its year-to-date and one-year returns.

Why is Rainbow Childrens Medicare Ltd falling/rising?

As of 23-Dec, Rainbow Childrens Medicare Ltd's stock price is rising, currently at 1,363.30, reflecting a change of 4.55 (0.33%) upwards. The stock has shown positive short-term performance but has underperformed in the long term, with significant declines year-to-date and a high valuation.

As of 23-Dec, Rainbow Childrens Medicare Ltd's stock price is rising, currently at 1,363.30, reflecting a change of 4.55 (0.33%) upwards. The stock has shown a positive performance today, outperforming its sector by 0.81%, and it has been on a consecutive gain streak for the last four days, accumulating a total return of 3.71% during this period.<BR><BR>In the short term, the stock has performed well, with a 1-week increase of 1.94% and a 1-month increase of 2.49%, both surpassing the respective returns of the Sensex. Additionally, the company demonstrates strong fundamentals, highlighted by a high Return on Capital Employed (ROCE) of 19.68% and a low Debt to EBITDA ratio of 0.84 times, indicating a solid ability to service its debt.<BR><BR>However, it is important to note that despite these positive indicators, the stock has underperformed in the long term, with a year-to-date decline of 9.00% and a 1-year drop of 11.51%. This underperformance contrasts sharply with the broader market, which has seen a 9.45% increase year-to-date. The stock's valuation is considered expensive, with a PEG ratio of 5.7, and it has shown poor long-term growth, with operating profit growing at an annual rate of only 14.50% over the past five years.<BR><BR>In summary, while Rainbow Childrens Medicare Ltd is experiencing a rise in its stock price due to recent gains and strong management efficiency, it faces challenges related to long-term growth and valuation that could impact its future performance.

Why is Rainbow Childrens Medicare Ltd falling/rising?

As of 24-Dec, the stock price of Rainbow Childrens Medicare Ltd is at 1,356.40, reflecting a decline due to underperformance relative to its sector, decreased delivery volume, and concerns over long-term growth despite strong management efficiency. The stock's high valuation and negative returns further contribute to its downward trend.

As of 24-Dec, the stock price of Rainbow Childrens Medicare Ltd is falling, currently at 1,356.40, reflecting a change of -2.35 (-0.17%). This decline can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed its sector today by -0.63%, indicating a weaker performance relative to its peers. Additionally, the stock's delivery volume has decreased significantly, with a drop of -22.35% against the 5-day average, suggesting a falling investor participation which can negatively impact stock price momentum.<BR><BR>While the company shows high management efficiency with a return on capital employed (ROCE) of 19.68% and a strong ability to service debt, these positive aspects are overshadowed by concerns regarding long-term growth. The operating profit has only grown at an annual rate of 14.50% over the last five years, and despite a recent increase in profits by 9.6%, the stock has generated a negative return of -11.73% over the past year, significantly underperforming the broader market which has seen a return of 6.20%.<BR><BR>Moreover, the stock is considered to have a very expensive valuation with a PEG ratio of 5.6, which may deter potential investors. The combination of these factors contributes to the stock's current downward trend.

Why is Rainbow Childrens Medicare Ltd falling/rising?

As of 25-Dec, the stock price of Rainbow Childrens Medicare Ltd is declining, currently at 1,356.40, due to underperformance against its sector, reduced investor participation, and concerns about long-term growth despite strong management efficiency. The stock's high valuation and negative returns further contribute to this downward trend.

As of 25-Dec, the stock price of Rainbow Childrens Medicare Ltd is experiencing a slight decline, currently at 1,356.40, reflecting a change of -2.35 (-0.17%). This decrease can be attributed to several factors highlighted in the provided data.<BR><BR>Firstly, the stock has underperformed its sector today by -0.63%, indicating a lack of momentum compared to its peers. Additionally, there has been a notable drop in investor participation, with the delivery volume on December 23 falling by -22.35% against the 5-day average. This decline in trading activity suggests a waning interest among investors, which can contribute to downward pressure on the stock price.<BR><BR>Moreover, while the company shows strong management efficiency with a high return on capital employed (ROCE) of 19.68% and a solid ability to service debt, these positive factors are overshadowed by concerns regarding long-term growth. The operating profit has only grown at an annual rate of 14.50% over the last five years, which raises questions about the company's future profitability. Additionally, the stock's valuation appears expensive, with a PEG ratio of 5.6, indicating that despite a rise in profits by 9.6% over the past year, the stock has generated negative returns of -11.73%, significantly underperforming the broader market, which has seen returns of 6.20% in the same period.<BR><BR>In summary, the combination of underperformance relative to the market, declining investor interest, and concerns about long-term growth prospects are contributing to the current decline in the stock price of Rainbow Childrens Medicare Ltd.